CSL Limited CSLLY
Set alert
35.39 USD +0.39 +1.11%
At close · Oct 30
35.30 Day range 35.48
16.01 52-week range 35.64
- YTD
- +22.88%
- 1 year
- +22.84%
- Open
- 35.48
- Prev close
- 35.00
- Mkt cap
- 67.93B
- Vol
- 830
- Avg vol
- 93.31K
- EPS
- -1.34
- P/E
- 0.00
More statistics
- Low
- 35.30
- High
- 35.48
3M chart
Events in this range
- Sep 10, 2026Dividend: 0.39051
Signals (8)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 27, 2026 | 6 days ago |
| RSI: Overbought | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2026 | Dec 31, 2025 | — | 0.055 | — | — |
| Feb 10, 2025 | Dec 31, 2024 | — | 0.2594 | — | — |
News
- CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
- CSL appoints Deborah Waterhouse as CEO & Managing Director
- Australia's CSL appoints Deborah Waterhouse as CEO
- HRMY vs. CSLLY: Which Stock Is the Better Value Option?
- CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras
- CSL strikes US$1.6 billion licensing deal for rare disease drug
- CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
- CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
- Australia's CSL taps Amazon's cloud unit to boost research pipeline
- Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Your note
Sign in to keep a note on CSLLY — it syncs with the Stock Master app.